Clinical Trial Update: A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1/2 study of Epofolate (BMS-753493) in subjects with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Epofolate (BMS-753493)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED